La vendita allo scoperto per Sangamo Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Sangamo Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Sangamo Therapeutics (NASDAQ:SGMO) Azioni, Report sulle vendite allo scoperto

Sangamo Therapeutics

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics Inc

WIIM

SGMO

Sangamo Therapeutics shares are trading higher after the company announced it gained FDA clearance status for its IND application of ST-503 to treat idiopathic small fiber neuropathy.

News

Sangamo Therapeutics Gains FDA Clearance For IND Application Of ST-503 To Treat Idiopathic Small Fiber Neuropathy, Aiming To Address Chronic Neuropathic Pain With Phase 1/2 Study Enrollment Set For Mid-2025

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $10 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

Sangamo Therapeutics shares are trading lower. The company reported Q3 financial results

Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.03) by 233.33 percent. This is a 106.78 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $49.41 million which beat the analyst consensus estimate of $17.94 million by 175.43 percent. This is a 425.77 percent increase over sales of $9.40 million the same period last year.

Earnings

Earnings Beats

Sangamo Therapeutics Q3 EPS $0.04 Beats $(0.03) Estimate, Sales $49.41M Beat $17.94M Estimate

U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/ZETA/earnings">third-quarter results</a>.
Total revenue rose 42% year-over-year to $268.3 million, while the company posted GAAP loss per share of 9 cents versus a year-ago loss of 27 cents per share.
Zeta Global shares dipped 9.8% to $33.15 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Destiny Tech100 Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NYSE">DXYZ</a>) declined 21.3% to $33.40 in pre-market trading after gaining 17% on Monday.</li>
<li>Agora, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) fell 13.8% to $4.32 in pre-market trading. Agora will release its financial results for the third quarter ended Sept. 30 after the closing bell on Nov. 25.</li>
<li>Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) shares declined 9.4% to $3.08 in pre-market trading after jumping over 25% on Monday.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) fell 8.5% to $2.47 in pre-market trading.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) fell 7.4% to $6.88 in pre-market trading.</li>
<li>Ouster, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) fell 7.2% to $9.79 in pre-market trading after jumping 32% on Monday.</li>
<li>Stepan Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCL#NYSE">SCL</a>) fell 5.5% to $75.14 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41877638/jim-cramer-tech-stock-go-to-160-recommends-buying-dominos-pizza">Jim Cramer: This Tech Stock Can &#8216;Go To 160,&#8217; Recommends Buying Domino&#8217;s Pizza</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

CIFR

DXYZ

OUST

SAVE

ZETA

Zeta Global, Spirit Airlines And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Sangamo Therapeutics to report an earnings per share (EPS) of $-0.03.
Anticipation surrounds Sangamo Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.03, which was followed by a 13.46% drop in the share price the next day.
Here's a look at Sangamo Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.15</td>
<td>-0.21</td>
<td>-0.26</td>
<td>-0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.18</td>
<td>-0.27</td>
<td>-0.34</td>
<td>-0.59</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-13.0%</td>
<td>7.000000000000001%</td>
<td>-1.0%</td>
<td>-22.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731341104_0.png" alt="eps graph" />
<h3>Sangamo Therapeutics Share Price Analysis</h3>
Shares of Sangamo Therapeutics were trading at $2.87 as of November 08. Over the last 52-week period, shares are up 763.58%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Sangamo Therapeutics</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Sangamo Therapeutics.
The consensus rating for Sangamo Therapeutics is Buy, based on 4 analyst ratings. With an average one-year price target of $6.25, there's a potential 117.77% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Regenxbio and Y-mAbs Therapeutics, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Regenxbio received a Buy consensus from analysts, with an average 1-year price target of $37.25, implying a potential 1197.91% upside.</li>
<li>Y-mAbs Therapeutics received a Outperform consensus from analysts, with an average 1-year price target of $21.0, implying a potential 631.71% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Regenxbio and Y-mAbs Therapeutics are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergent BioSolutions</td>
<td>Buy</td>
<td>-25.11%</td>
<td>$-48M</td>
<td>-53.91%</td>
</tr>
<tr>
<td>Regenxbio</td>
<td>Buy</td>
<td>-16.31%</td>
<td>$11.81M</td>
<td>-18.35%</td>
</tr>
<tr>
<td>Y-mAbs Therapeutics</td>
<td>Outperform</td>
<td>9.86%</td>
<td>$19.78M</td>
<td>-9.51%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Sangamo Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, indicating lower performance compared to its peers. However, it ranks in the middle for Return on Equity, suggesting average profitability. Overall, Sangamo Therapeutics lags behind its peers in terms of financial performance based on the provided metrics.
<h3>Delving into Sangamo Therapeutics's Background</h3>
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
<h3>Key Indicators: Sangamo Therapeutics's Financial Health</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Decline in Revenue: Over the 3 months period, Sangamo Therapeutics faced challenges, resulting in a decline of approximately -94.79% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Sangamo Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -10148.31% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sangamo Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -89.89%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Sangamo Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -32.55%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Sangamo Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 1.23. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/SGMO/earnings">To track all earnings releases for Sangamo Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sangamo Therapeutics's Earnings Outlook

Sangamo Therapeutics shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $5 to $10.

HC Wainwright &amp; Co. analyst Patrick Trucchio maintains Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and raises the price target from $5 to $10.

HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Raises Price Target to $10

U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Friday.
Shares of Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) rose sharply during Friday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/10/41543105/government-and-military-contractor-booz-allen-clocks-strong-q2-performance-backlog-expands-to-41-3b">quarterly EPS and sales.</a>
Booz Allen Hamilton reported fiscal second-quarter adjusted EPS of $1.81, topping the analyst consensus estimate of $1.49. Quarterly sales of $3.15 billion, up 18% year-on-year, beat the street view of $2.97 billion. The backlog grew by 17.7%, reaching $41.3 billion, while the quarterly book-to-bill ratio stood at 2.61x.
Booz Allen Hamilton shares jumped 10% to $183.21 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) shares jumped 49.6% to $6.30. ImmunityBio recently announced it dosed its first patients in its Phase 1 clinical study of CAR-NK cell therapy for relapsed B-Cell Non-Hodgkin Lymphoma.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) gained 32.4% to $29.50.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) climbed 22.8% to $8.81 after the company reported third-quarter financial results and raised its 2024 guidance.</li>
<li>ZEEKR Intelligent Technology Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NASDAQ">ZK</a>) gained 21.5% to $28.08.</li>
<li>Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) gained 13.3% to $50.37 following a report alleging that a judge blocked the company&#8217;s proposed acquisition of Capri. The company issued a statement on the ruling saying it intends to appeal the decision.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) rose 11.7% to $1.6650.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) gained 11.2% to $38.85.</li>
<li>AppFolio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) gained 10.4% to $211.98 after the company reported better-than-expected quarterly financial results and raised its FY24 revenue guidance. Also, Piper Sandler maintained an Overweight rating on the stock.</li>
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) rose 10.2% to $167.53 after the company reported better-than-expected second-quarter financial results.</li>
<li>Digital Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) gained 10.2% to $182.01 after the company reported better-than-expected third-quarter FFO results and raised its FY24 FFO guidance.</li>
<li>Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) gained 9.2% to $452.58 following strong quarterly sales.</li>
<li>Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) surged 6.7% to $68.60 after the company reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<a href="https://www.benzinga.com/news/24/10/41545983/this-ppl-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday">This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday</a>

Intraday Update

APPF

DECK

FTEL

IBRX

SAIA

Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 92.5% to $0.3 during Wednesday's regular session. The company's market cap stands at $9.6 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) stock rose 63.89% to $2.75. The market value of their outstanding shares is at $11.9 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 59.31% to $2.56. The company's market cap stands at $437.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 42.54% to $1.0. The company's market cap stands at $95.9 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares increased by 36.35% to $1.65. The company's market cap stands at $343.5 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 22.47% to $4.12. The market value of their outstanding shares is at $32.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) shares declined by 66.1% to $4.93 during Wednesday's regular session. The market value of their outstanding shares is at $132.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 27.74% to $0.33. The market value of their outstanding shares is at $4.4 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 26.44% to $0.4. The company's market cap stands at $5.4 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 25.26% to $0.72. The market value of their outstanding shares is at $2.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 25.18% to $1.07. The company's market cap stands at $2.1 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock fell 23.73% to $1.8. The market value of their outstanding shares is at $3.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANRO

BIVI

CNSP

CYCC

DBVT

ENSC

ALPS ETF Trusthen & Steers Global Realty Majors ETF

NUWE

SLXN

TVGN

VRAX

12 Health Care Stocks Moving In Wednesday's Intraday Session

Sangamo Therapeutics shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.0, a high estimate of $5.00, and a low estimate of $5.00. This current average has not changed from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1729684823_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Sangamo Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sangamo Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sangamo Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sangamo Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SGMO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sangamo Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Sangamo Therapeutics</h2>
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
<h3>Financial Insights: Sangamo Therapeutics</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Sangamo Therapeutics faced challenges, resulting in a decline of approximately -94.79% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Sangamo Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -10148.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Sangamo Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -89.89%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -32.55%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.23, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Have This To Say About Sangamo Therapeutics

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $5 price target.

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.2% on Tuesday.
The Dow traded up 0.08% to 42,963.84 while the NASDAQ gained 0.18% to 18,573.16. The S&amp;P 500, however, fell 0.02% to 5,852.75 during the session.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41426981/top-4-consumer-stocks-that-may-dip-this-quarter">Top 4 Consumer Stocks That May Dip This Quarter</a>
Leading and Lagging Sectors Consumer staples shares rose by 0.8% on Tuesday.
In trading on Monday, industrials shares fell by 1%.
Top Headline
Shares of Verizon Communications Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) fell around 5% on Tuesday after it reported fiscal third-quarter results.
Its sales growth was flat year over year, reaching $33.33 billion, marginally missing the analyst consensus estimate of $33.43 billion. Service and other revenue growth was offset by declines in wireless equipment revenue. Adjusted EPS of $1.19 beat the analyst consensus estimate of $1.18.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) shares shot up 22% to $75.59 after the company announced that it was granted FDA clearance for its 510(k) submission related to prior design changes made to the Zio AT device.</li>
<li>Shares of Mueller Industries, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>) got a boost, surging 16% to $83.35 after the company reported better-than-expected third-quarter sales results.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares were also up, gaining 37% to $1.2499 after the company announced the FDA approved an accelerated pathway for ST-920 in Fabry disease. A BLA submission is expected in 2025.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) shares dropped 19% to $115.37 after the company reported mixed third-quarter financial results and cut its FY24 EPS below estimates.</li>
<li>Shares of Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) were down 8% to $73.50 after the company reported worse-than-expected third-quarter EPS and sales and cut its 2024 guidance.</li>
<li>Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) was down, falling 8% to $84.04 following second-quarter results.</li>
</ul>
Commodities In commodity news, oil traded up 2.1% to $72.06 while gold traded up 0.8% at $2,761.40.
Silver traded up 2.9% to $35.050 on Tuesday, while copper rose 0.7% to $4.3890.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.21%, Germany's DAX fell 0.20% and France's CAC 40 fell 0.01%. Spain's IBEX 35 Index fell 0.07%, while London's FTSE 100 fell 0.14%.
Passenger car registrations in the European Union fell by 6.1% year-over-year to 809,163 units in September following a 18.3% decline in August.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 1.39%, Hong Kong's Hang Seng Index gaining 0.1%, China's Shanghai Composite Index gaining 0.54% and India's BSE Sensex falling 1.15%.
The annual inflation rate in Hong Kong fell to 2.2% in September from 2.5% in the prior month.
Economics
The composite manufacturing index in the US Fifth District came in at -14 for October compared to a reading of -21 in the prior month.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41453972/top-3-defensive-stocks-that-may-keep-you-up-at-night-this-month">Top 3 Defensive Stocks That May Keep You Up At Night This Month</a></li>
</ul>

IRTC

LOGI

Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results

Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares are moving higher Tuesday after the company announced the FDA approved an accelerated pathway for ST-920, a potential gene therapy for the treatment of <a href="https://www.benzinga.com//node/41449489">Fabry disease</a>.
What To Know: The FDA&#8217;s approval of the accelerated pathway was based on data from the ongoing Phase 1/2 STAAR study. Without an accelerated pathway, the company would have to conduct an additional study. Tuesday&#8217;s announcement will allow Sangamo to forego the extra study, speeding up the estimated time to potential approval by approximately three years.
The data from the ongoing study showed promising safety and efficacy results and evidence of improved kidney function. These improvements, particularly in estimated glomerular filtration rate (eGFR), an indicator of kidney function, suggest the potential to address the renal complications commonly seen in Fabry disease.
&#8220;Fabry is a debilitating disease, for which there is a serious unmet medical need,&#8221; said Sandy Macrae, CEO of Sangamo. 
&#8220;I strongly believe in the potential for ST-920 to alleviate many manifestations of Fabry disease and am delighted to have a clear regulatory pathway that could bring this treatment to patients significantly sooner than originally anticipated&#8221;.
Sangamo said it has begun to execute Biologics License Application (BLA) readiness activities and expects to submit a BLA during the second half of 2025.
See Also: <a href="https://www.benzinga.com/news/24/10/41415824/lucid-ceo-peter-rawlinson-talks-saudi-investment-elon-musks-political-views-and-taking-business-from">Lucid CEO Peter Rawlinson Talks Saudi Investment, Elon Musk&#8217;s Political Views And Taking Business From Tesla</a>
How To Buy Sangamo Therapeutics Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Sangamo Therapeutics's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
SGMO Price Action: At the time of writing, Sangamo shares are up 33.7% at $1.21, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: Courtesy of Sangamo Therapeutics.

What's Going On With Sangamo Therapeutics Shares Tuesday?

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday.
The Dow traded down 0.09% to 42,891.94 while the NASDAQ slipped 0.28% to 18,488.16. The S&amp;P 500 also fell, dropping, 0.30% to 5,836.28.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41426981/top-4-consumer-stocks-that-may-dip-this-quarter">Top 4 Consumer Stocks That May Dip This Quarter</a>
Leading and Lagging Sectors Energy shares rose by 0.5% on Tuesday.
In trading on Monday, industrials shares fell by 1.1%.
Top Headline
3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) reported better-than-expected third-quarter adjusted EPS and sales and revised FY24 EPS guidance.
The company reported net sales of $6.294 billion, a slight increase of 0.4% year-over-year. Adjusted net sales totaled $6.068 billion, up 1.5% on year and marginally beating the consensus of $6.057 billion. Adjusted EPS was $1.98, up 18% Y/Y, beating the consensus of $1.90.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) shares shot up 20% to $74.21 after the company announced that it was granted FDA clearance for its 510(k) submission related to prior design changes made to the Zio AT device.</li>
<li>Shares of Mueller Industries, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>) got a boost, surging 16% to $83.91 after the company reported better-than-expected third-quarter sales results.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares were also up, gaining 40% to $1.2787 after the company announced the FDA approved an accelerated pathway for ST-920 in Fabry disease. A BLA submission is expected in 2025.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) shares dropped 20% to $114.60 after the company reported mixed third-quarter financial results and cut its FY24 EPS below estimates.</li>
<li>Shares of Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) were down 11% to $71.71 after the company reported worse-than-expected third-quarter EPS and sales and cut its 2024 guidance.</li>
<li>Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) was down, falling 10% to $83.01 following second-quarter results.</li>
</ul>
Commodities In commodity news, oil traded up 2.8% to $72.54 while gold traded up 0.5% at $2,753.70.
Silver traded up 2.4% to $34.900 on Tuesday, while copper rose 0.3% to $4.3745.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.21%, Germany's DAX fell 0.20% and France's CAC 40 fell 0.01%. Spain's IBEX 35 Index fell 0.07%, while London's FTSE 100 fell 0.14%.
Passenger car registrations in the European Union fell by 6.1% year-over-year to 809,163 units in September following a 18.3% decline in August.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 1.39%, Hong Kong's Hang Seng Index gaining 0.1%, China's Shanghai Composite Index gaining 0.54% and India's BSE Sensex falling 1.15%.
The annual inflation rate in Hong Kong fell to 2.2% in September from 2.5% in the prior month.
Economics
The composite manufacturing index in the US Fifth District came in at -14 for October compared to a reading of -21 in the prior month.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41453972/top-3-defensive-stocks-that-may-keep-you-up-at-night-this-month">Top 3 Defensive Stocks That May Keep You Up At Night This Month</a></li>
</ul>

Equities

Eurozone

Commodities

Crude Oil Rises Sharply; 3M Posts Upbeat Earnings

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 120.0% to $0.45 during Tuesday's regular session. The company's market cap stands at $6.2 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 102.48% to $0.45. The market value of their outstanding shares is at $8.1 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares rose 90.15% to $2.87. The company's market cap stands at $7.4 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares increased by 41.29% to $1.29. The company's market cap stands at $268.6 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares increased by 31.15% to $3.45. The market value of their outstanding shares is at $27.5 million. </li>
<li>Werewolf Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>) shares increased by 28.61% to $3.67. The market value of their outstanding shares is at $160.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock fell 30.5% to $0.33 during Tuesday's regular session. The market value of their outstanding shares is at $23.9 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock fell 28.74% to $0.94. The company's market cap stands at $2.7 million. </li>
<li>Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) stock decreased by 19.52% to $6.17. The company's market cap stands at $336.1 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock decreased by 17.86% to $1.84. The market value of their outstanding shares is at $28.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares decreased by 17.15% to $5.22. The company's market cap stands at $3.4 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock declined by 16.65% to $0.65. The market value of their outstanding shares is at $16.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GNPX

HOWL

INAB

ISPC

NDRA

SNSE

VSEE

VYGR

12 Health Care Stocks Moving In Tuesday's Intraday Session

TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMO stock, giving a Buy rating yesterday. Ritu Baral has given her Buy rating d...

Sangamo Biosciences: Promising Financial Position and Strategic FDA Alignment Drive Buy Rating

Sangamo Biosciences (SGMO) has disclosed a new risk, in the Manufacturing category. Sangamo Biosciences does not face any business risks related to...

Sangamo Biosciences: Mine Safety Regulations Pose No Risk to Operations

Wells Fargo analyst Yanan Zhu assigned a Hold rating to Sangamo Biosciences (SGMO – Research Report) yesterday and set a price target of $3.00. The...

Wells Fargo Gives a Hold Rating to Sangamo Biosciences (SGMO)

Wells Fargo raised the firm's price target on Sangamo (SGMO) to $3 from $1 and keeps an Equal Weight rating on the shares. The firm views partnersh...

Sangamo price target raised to $3 from $1 at Wells Fargo

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of $1...

Sangamo Biosciences: Strategic Advancements and Collaborations Bolster Buy Rating

The company states: "Sangamo (SGMO) Therapeutics announced that the FDA has cleared the investigational new drug application for its ST-503 program...

Sangamo gets FDA clearance of IND application for ST-503 in iSFN

16:17 EST Sangamo (SGMO) up 11% at $2.17 on FDA clearing IND for ST-503 Published first on TheFly – the ultimate source for real-time, market-movin...

Sangamo up 11% at $2.17 on FDA clearing IND for ST-503

Sangamo stock climbs 12% post-market on FDA update for ST-503

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp; HIGHER AFTER EARNINGS – KORE Group Holdings&nbsp;(KORE)&nbs...

Closing Bell Movers: Keysight up 9% after Q4 earnings beat

Q3 2024 Earnings: Hold Akebia Therapeutics

AKBA

AVAV

AZEK

FDMT

FLEX

KEYS

KORE

LRMR

POWL

PRME

SNEX

VREX

WKHS

Press Releases

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

Comments

Sangamo Therapeutics

Vendite allo scoperto

Sangamo Therapeutics (NASDAQ:SGMO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO